FDA grants accelerated approval to Vera's Trutakna for IgA nephropathy, first dual BAFF/APRIL inhibitor. Competes with ...
Landmark agreement between a leading virtual care company and a pharmaceutical manufacturer establishes an exclusive telehealth co-marketing ...
DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("DRI Healthcare") today commented on Viridian Therapeutics, Inc.'s ("Viridian") recently announced approval by the U.S. Food and Drug Administration ...
DRI Healthcare Trust ("DRI Healthcare") today commented on Viridian Therapeutics, Inc.'s ("Viridian") recently announced ...
Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye Disease June 29, 2026 8:00 ...
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that it recently received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for the Phase I study ...
The global long-acting drugs market is growing steadily, expected to be valued at around US$ 7.2 billion in 2026 and ...
Halozyme Therapeutics, Inc. ("Halozyme" or the "Company") today announced the appointment of David Ramsay as President Drug ...
The global long-acting drugs market is growing steadily, expected to be valued at around US$ 7.2 billion in 2026 and projected to reach US$ 13.3 billion ...
Backed by data from the phase 3 SatraGO trials, satralizumab has the potential to offer patients a convenient, at-home treatment option.
The European Commission has approved Sarclisa (isatuximab) subcutaneous (SC) in combination with standard-of-care regimens for the treatment of patients with multiple myeloma (MM) across all existing ...
Lifordi Immunotherapeutics, Inc., a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) for the treatment of autoimmune and inflammatory disorders, presented first-in-human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results